Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ...

Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ...

Data Highlights Transformative Promise of CAR T in Solid TumorsPhase 1 Trial with ALLO-316 Demonstrated Potential to Provide Meaningful Clinical Benefit in Patients with CD70 TPS ≥ 50% Advanced or Metastatic RCCA Single Dose of ALLO-316 Achieved a 31% Confirmed…

Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO

June 01, 2025 10:45 ET  | Source: Allogene Therapeutics, Inc. Data Highlights Transformative Promise of CAR T in Solid Tumors Phase 1 Trial with ALLO-316 Demonstrated Potential to Provide Meaningful Clinical Benefit in Patients with CD70 TPS ≥ 50% Advanced or Metastatic RCC A Single Dose of ALLO-316 Achieved a 31% Confirmed Response Rate Four […]

Breakthrough in Solid Tumors: ALLO-316 CAR T Therapy Achieves 12-Month Remission in Advanced Kidney Cancer

Latest Phase 1 data reveals durable responses in treatment-resistant renal cell carcinoma. First allogeneic CAR T success in solid tumors. See complete results.